Five PubMed papers to open first: a triple-agonist obesity drug, oral breast-cancer therapy, an 8-week hepatitis C cure, paid smoking cessation, and robotic joint replacement
A ranked 10-minute triage of five papers entered in PubMed from September 29 to October 6, 2026: a phase 3 triple-agonist obesity trial, an all-oral regimen for ESR1-mutated advanced breast cancer, an eight-week hepatitis C cure, financial incentives for smoking cessation in underserved patients, and national registry comparisons of robotic hip and knee replacement.
This issue covers the papers that entered PubMed between September 29 and October 6, 2026, dated by each record's PubMed entry date. The week's centre of gravity was metabolic medicine and oncology: a first-in-class triple-agonist obesity drug published its phase 3 results in full, an all-oral endocrine pair reported a large progression-free-survival gain in advanced breast cancer, and a hepatitis C trial tested a shorter cure, alongside a pragmatic smoking-cessation trial in underserved patients and national registry comparisons of robotic hip and knee replacement. Citation counts stay flat at this age — across Crossref, OpenAlex, and Europe PMC the highest count for any of the five is one cited-by work, and four sit at zero — so the order runs on journal tier first, then on randomized design, sample size, endpoint strength, and how directly a result changes a treatment, screening, or surgery decision. The table carries every count, so you can re-rank the five yourself.
At a glance
| Rank | Paper | Journal and tier | Design and sample | Primary result | Early cited-by signal |
|---|---|---|---|---|---|
| 1 | Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity 1 | The New England Journal of Medicine; very high impact tier | Phase 3, randomized, double-blind, placebo-controlled, 80 weeks; 2,339 adults with obesity and without diabetes | Body weight −25.0% at 12 mg and −23.7% at 9 mg vs −3.9% with placebo (differences −21.0 and −19.8 percentage points; P<0.001) | 0 2 |
| 2 | Giredestrant plus Everolimus in Advanced Breast Cancer 3 | The New England Journal of Medicine; very high impact tier | Phase 3, randomized, open-label; 373 patients with ER-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor | Median progression-free survival in ESR1-mutated tumors 10.0 vs 5.5 months (HR 0.38, 95% CI 0.27–0.54; P<0.001) | 0 4 |
| 3 | 8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE) 5 | The Lancet; very high impact tier | Multicentre, randomized, open-label, non-inferiority trial at five publicly funded hospitals in India; 880 adults with non-cirrhotic chronic hepatitis C | Sustained virological response at 12 weeks, per protocol: 98.8% with 8 weeks vs 99.0% with 12 weeks (risk difference 0.2%, 95% CI −1.5 to 1.9) | 0 6 |
| 4 | Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening 7 | JAMA; very high impact tier | Four-arm randomized trial, single-masked, at four US health systems; 3,259 medically underserved adults | Biochemically confirmed sustained abstinence through 6 months 8.8% with financial incentives vs 4.3% with usual care (difference 4.6%, 95% CI 2.1%–7.0%; P<.001) | 0 8 |
| 5 | Robotic versus conventional hip and knee replacement using National Joint Registry data 910 | BMJ; very high impact tier | Two target-trial-emulation studies of national registry data, 2018–2024, propensity-score matched; 666,283 hip and 697,145 knee procedures | Five-year implant survival hip 98.8% vs 98.8% (revision HR 0.96, 95% CI 0.75–1.22); knee 98.5% vs 98.6% (HR 1.03, 95% CI 0.86–1.26) | 1 each 1112 |
1. A triple-agonist obesity drug reaches peer-reviewed phase 3: mean weight falls 25% over 80 weeks
Journal and impact tier: The New England Journal of Medicine, very high impact tier. PubMed entered the paper on September 29, 2026, under PMID 42814954. 1
Author and affiliation: First author Ania M. Jastreboff is in the Department of Medicine (Endocrinology and Metabolism) and the Yale Obesity Research Center at Yale University School of Medicine, in New Haven, Connecticut; the closing author, Yan Wang, is at Eli Lilly in Indianapolis. The report is issued for the TRIUMPH-1 Investigators. 1
Design, setting, and sample: TRIUMPH-1 is a phase 3, randomized, double-blind, placebo-controlled trial in adults with obesity who did not have diabetes. Participants gave themselves a once-weekly subcutaneous injection of retatrutide at 4 mg, 9 mg, or 12 mg, or a placebo, for 80 weeks. 2,339 participants were randomly assigned. The registry lists a completed phase 3 study at 134 locations across at least 12 countries, sponsored by Eli Lilly, with primary completion recorded in April 2026. 13 The trial set three co-primary outcomes: the percent change in body weight, the change in the WOMAC pain score among the 574 participants with knee osteoarthritis, and the change in the apnea–hypopnea index among the 243 participants with obstructive sleep apnea. 1
Primary endpoint and quantitative result: Mean body weight fell 17.6% at 4 mg, 23.7% at 9 mg, and 25.0% at 12 mg, against 3.9% with placebo; the differences from placebo were −19.8 percentage points at 9 mg and −21.0 at 12 mg, both P<0.001. In the knee-osteoarthritis subgroup the WOMAC pain score, which runs from 1 to 10 with higher scores meaning worse pain, fell to 3.6 at 12 mg against 1.9 with placebo (difference −1.8 points; P<0.001), and in the sleep-apnea subgroup the apnea–hypopnea index fell by 34.3 events per hour at 9 mg and 31.7 at 12 mg, against 9.9 with placebo — differences of −24.4 and −21.9 events per hour, both P<0.001. Gastrointestinal events were the most common adverse events reported. 1
Why it matters: Retatrutide activates the GIP, GLP-1, and glucagon receptors at once, and this is the first peer-reviewed phase 3 report of the compound in obesity. The trial puts its three endpoints in the two populations where obesity most often forces a clinical decision, knee osteoarthritis and obstructive sleep apnea, and it reports improvements in pain and in nighttime breathing alongside the weight change. For a clinician weighing what the next generation of incretin drugs will offer, the 12-mg result is the number to hold: a mean 25% reduction in body weight over 80 weeks in people who did not have diabetes. 1
Limitation and evidence boundary: The trial enrolled adults with obesity and without diabetes, so its answer covers that group rather than the larger population of obesity with type 2 diabetes. The knee-osteoarthritis and sleep-apnea results come from subgroups of 574 and 243 participants, and the main efficacy endpoint is total body weight, which does not by itself separate fat from lean tissue. Eighty weeks is long for a weight-loss trial and short against the decades over which a drug of this kind would be taken. 1
Funding or disclosure: Funded by Eli Lilly, the developer of retatrutide; registered as TRIUMPH-1, NCT05929066. 13
2. An all-oral endocrine pair doubles progression-free survival in ESR1-mutated advanced breast cancer
Journal and impact tier: The New England Journal of Medicine, very high impact tier; volume 395, issue 13. PubMed entered the paper on October 1, 2026, under PMID 42814929. 3
Author and affiliation: First author Erica L. Mayer is at the Dana-Farber Cancer Institute in Boston; the closing author, Hope S. Rugo, is at the City of Hope Comprehensive Cancer Center in Duarte, California. The report is issued for the evERA Breast Cancer Investigators. 3
Design, setting, and sample: evERA is a phase 3, randomized, open-label trial in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer whose disease had progressed or recurred after a CDK4/6 inhibitor plus endocrine therapy. Patients were assigned 1:1 to giredestrant plus everolimus, both given by mouth, or to standard endocrine therapy — exemestane, fulvestrant, or tamoxifen — plus everolimus. 373 patients were randomly assigned, 183 to the giredestrant pair and 190 to standard therapy. The registry lists a completed phase 3 enrollment of 373 at 136 locations, sponsored by Genentech, with primary completion recorded in July 2025. 14 The primary endpoint was investigator-assessed progression-free survival, tested first in patients whose tumors carried an ESR1 mutation and then in the overall trial population. 3
Primary endpoint and quantitative result: Among the 207 patients with ESR1-mutated tumors, median progression-free survival was 10.0 months with giredestrant plus everolimus against 5.5 months with standard therapy plus everolimus (hazard ratio for progression or death 0.38, 95% CI 0.27 to 0.54; P<0.001). In the overall population it was 8.8 months against 5.5 months (hazard ratio 0.56, 95% CI 0.44 to 0.71; P<0.001). Adverse events occurred in 98.9% of patients given the giredestrant pair and 96.8% of those given standard therapy, with stomatitis, diarrhea, and anemia the most common in both arms. 3
Why it matters: After a CDK4/6 inhibitor fails, ESR1 mutations are a common route to further endocrine resistance, and giredestrant is an oral selective estrogen receptor degrader built to work against them. The trial's answer is a doubling of median progression-free survival in the ESR1-mutated group on a regimen where every drug comes as a tablet, which matters for patients who have already spent months on intravenous therapy. The overall-population hazard ratio of 0.56 shows the same direction with a smaller effect, which is what you would expect when a targeted benefit is diluted across a mixed group. 3
Limitation and evidence boundary: The trial was open-label, and progression-free survival was assessed by the investigators rather than by a blinded review committee. It enrolled 373 patients, so the ESR1-mutated analysis rests on 207 people, and the report measured time to progression rather than overall survival. The benefit is concentrated in the ESR1-mutated subgroup, which means the trial speaks most directly to patients whose tumors carry that mutation. 3
Funding or disclosure: Funded by Genentech, the developer of giredestrant; registered as evERA Breast Cancer, NCT05306340. 14
3. Hepatitis C treatment cut from twelve weeks to eight, with the cure rate intact
Journal and impact tier: The Lancet, very high impact tier. PubMed entered the paper on September 30, 2026, under PMID 42815507. 5
Author and affiliation: First author Amit Goel is in the Department of Hepatology at the Sanjay Gandhi Postgraduate Institute of Medical Sciences in Lucknow, India, and corresponding author Rakesh Aggarwal is in the Department of Gastroenterology at the same institute. The trial ran at five publicly funded hospitals in India. 5
Design, setting, and sample: RESOLVE is a multicentre, randomized, open-label, non-inferiority trial in treatment-naive adults aged 18 or older with chronic hepatitis C virus infection and no evidence of cirrhosis. Participants were assigned 1:1 to sofosbuvir 400 mg plus velpatasvir 100 mg, taken by mouth once daily, for either 8 weeks or 12 weeks. 880 people were enrolled between May 2022 and September 2024 — 443 in the 8-week group and 437 in the 12-week group — with a median age of 35 years and 52% women. The primary outcome was sustained virological response at 12 weeks after treatment, meaning no quantifiable hepatitis C RNA, tested per protocol with a 5% non-inferiority margin. The trial is registered with the Clinical Trial Registry of India as CTRI/2022/03/041368 and is complete. 5
Primary endpoint and quantitative result: On the per-protocol analysis, sustained virological response at 12 weeks was reached by 98.8% of the 8-week group (410 of 415) against 99.0% of the 12-week group (397 of 401), a risk difference of 0.2% (95% CI −1.5 to 1.9) — inside the non-inferiority margin. On the intention-to-treat analysis the proportions were 93.5% against 91.8%, a risk difference of −1.7% (95% CI −5.2 to 1.9). No participant had a drug-related serious adverse event or stopped treatment because of an adverse event. 5
Why it matters: Direct-acting antiviral regimens cure most people with chronic hepatitis C, and the obstacle in many health systems is cost and the length of the course rather than the drug's effectiveness. Cutting four weeks off a cure that already works reduces the price of each treated patient and the number of visits a course requires, which is the arithmetic that hepatitis C elimination programmes run on. The result applies to people without cirrhosis and without prior treatment, which is the group this regimen is licensed for. 5
Limitation and evidence boundary: The trial was open-label and ran entirely in India, so its result speaks to that population and to the genotypes circulating there. It enrolled only treatment-naive adults without cirrhosis, and the primary analysis was per protocol, which sets aside the participants who did not complete treatment and testing. The endpoint is viral clearance at 12 weeks after treatment rather than long-term liver outcomes such as cirrhosis or liver cancer. 5
Funding or disclosure: Funded by the Indian Council of Medical Research, Department of Health Research, Government of India; registered as CTRI/2022/03/041368. 5
4. Financial incentives double six-month abstinence for underserved patients in lung-cancer screening
Journal and impact tier: JAMA, very high impact tier. PubMed entered the paper on October 5, 2026, under PMID 42832220. 7
Author and affiliation: First author Joanna L. Hart is in the Department of Medicine at the Perelman School of Medicine, University of Pennsylvania, in Philadelphia; the closing author, Scott D. Halpern, is in the same department. The trial ran at four US health systems and five centres, sponsored by the Abramson Cancer Center at Penn Medicine with the Patient-Centered Outcomes Research Institute as a collaborator. 15
Design, setting, and sample: This is a four-arm, randomized, single-masked trial in people who smoked and had been referred for lung-cancer screening, recruited from groups the trial defines as medically underserved — Black, Hispanic, rural, or of low socioeconomic status. 3,259 people were randomly assigned and 3,220 entered the primary analysis. The arms were an ask-advise-refer strategy to cessation services alone; that strategy plus free pharmacotherapy; the same plus financial incentives of up to $600 contingent on biochemically confirmed abstinence; and the same plus a mobile health tool motivating patients to consider their future health. The median age was 61.1 years, 60.3% were women, 25.5% were Black, 8.9% were Hispanic, 38.8% lived in rural areas, and 74.9% had low socioeconomic status. The primary endpoint was biochemically confirmed sustained tobacco abstinence through 6 months. 7
Primary endpoint and quantitative result: Sustained abstinence through 6 months was reached by 4.3% with usual care, 5.1% with added pharmacotherapy, 8.8% with added financial incentives, and 7.2% with the mobile health tool. Adding financial incentives raised the adjusted rate by 4.6 percentage points over usual care (95% CI 2.1% to 7.0%; P<.001) and by 4.1 percentage points over usual care plus free pharmacotherapy (95% CI 1.7% to 6.4%; P<.001). Adding free pharmacotherapy to the ask-advise-refer strategy produced a difference of 0.5 percentage points (95% CI −1.7% to 2.6%; P=.66). 7
Why it matters: Medicare and Medicaid require health systems to offer cessation services to people undergoing lung-cancer screening, and the practical question is what to offer. In this trial, free pharmacotherapy on top of a referral changed the abstinence rate very little, while paying for confirmed abstinence moved it most — roughly one extra sustained quitter for every 22 people offered incentives. An accompanying JAMA comment weighs the case for treatment alongside the screening programme. 16
Limitation and evidence boundary: Participants and the people delivering the intervention knew the assignment, and only the outcome measurement was kept at arm's length, so the design is single-masked rather than fully blinded. The trial's absolute abstinence rates across all arms sit between 4% and 9% at six months, so incentives improve a low baseline. The endpoint is six months of abstinence, which sits short of the years that determine whether the cardiovascular and cancer risk actually falls. 7
Funding or disclosure: Sponsored by the Abramson Cancer Center at Penn Medicine, with the Patient-Centered Outcomes Research Institute as a collaborator; registered as NCT04798664. 15
5. Robotic hip and knee replacement matches conventional surgery on revisions, at higher cost
Journal and impact tier: BMJ, very high impact tier; volume 394. Two linked papers entered PubMed on September 30, 2026: the hip-replacement comparison under PMID 42815970 and the knee-replacement comparison under PMID 42815981. 910
Author and affiliation: Both reports share the same four authors. First and corresponding author Hasan R. Mohammad is in Bone and Joint Health at the Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London; the closing author, David W. Murray, is in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford. 9
Design, setting, and sample: Each paper is a target-trial-emulation study built on the National Joint Registry of England, Wales, Northern Ireland, the Isle of Man, Guernsey, and Jersey, covering operations from 2018 to 2024 and using propensity-score matching to build comparable groups. The hip study covers 666,283 total hip replacements, of which 10,203 were robotic and 656,080 conventional; the knee study covers 697,145 knee replacements, of which 22,111 were robotic and 675,034 conventional, spanning total and unicompartmental knee replacement. The matched groups were followed for a mean of 2.5 years, with the main outcome being five-year implant survival and the risk of revision surgery. 910
Primary endpoint and quantitative result: Five-year implant survival was 98.8% in both the matched robotic and conventional hip groups (revision hazard ratio 0.96, 95% CI 0.75 to 1.22; P=0.73), and 98.5% against 98.6% for matched total knee replacement (hazard ratio 1.03, 95% CI 0.86 to 1.26; P=0.71). In the hip study, revisions for implant malpositioning — dislocation, leg-length discrepancy, and malalignment — were less common with robotic surgery (hazard ratio 0.53, 95% CI 0.30 to 0.93; P=0.03), and cause-specific revision risk and intraoperative complications did not differ between groups in either paper. An accompanying BMJ editorial asks whether the technology justifies its capital and procedural cost. 17
Why it matters: Robotic joint replacement systems cost health systems a large sum in capital and in each operation, and the case for them has rested on positioning accuracy rather than on whether patients keep their implants longer. Against more than 1.3 million operations, the two papers find the revision rates effectively level, with a narrower benefit in hips confined to revisions for malpositioning. That is the comparison a commissioner weighing a purchase needs, and the linked editorial reads it the same way. 9
Limitation and evidence boundary: Both papers are retrospective and observational, so matching can only control for the variables the registry records; robotic procedures in the unmatched data went to younger, healthier patients treated by higher-volume surgeons, and residual confounding from patient selection and care pathways remains possible. Follow-up averages 2.5 years, which is short for an implant expected to last decades. The papers include no patient-reported measures of pain and function, so they say nothing about whether robotic surgery feels better to the patient; the authors point to the RACER-hip trial for that question. 910
Funding or disclosure: The hip study states that no specific funding was received; the reports draw on National Joint Registry data held under its research subcommittee's permission. 9
What to open first
- A triple-agonist obesity drug: Open TRIUMPH-1 if your question is how much weight a GIP–GLP-1–glucagon agonist removes over 80 weeks, and what its phase 3 report says about knee pain and sleep apnea in the same population. 1
- Advanced breast cancer after a CDK4/6 inhibitor: Open evERA if your question is how much an all-oral giredestrant–everolimus pair extends progression-free survival in ESR1-mutated tumors, and how the effect dilutes in the overall population. 3
- Chronic hepatitis C without cirrhosis: Open RESOLVE if your question is whether eight weeks of sofosbuvir-velpatasvir holds the cure rate that twelve weeks achieves, and what that shortens in cost and visits. 5
- Smoking cessation inside a screening programme: Open the JAMA trial if your question is which add-on actually raises abstinence among underserved patients referred for lung-cancer screening, and where free pharmacotherapy lands. 7
- Robotic joint replacement: Open the two BMJ registry papers if your question is whether robotic hip and knee replacement changes revision risk enough to justify its cost, and how much of the apparent benefit comes from patient selection. 910
References
- 1Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
pubmed.ncbi.nlm.nih.gov
- 2OpenAlex record for the TRIUMPH-1 report
openalex.org
- 3Giredestrant plus Everolimus in Advanced Breast Cancer
pubmed.ncbi.nlm.nih.gov
- 4OpenAlex record for the evERA report
openalex.org
- 58 weeks versus 12 weeks of sofosbuvir-velpatasvir (RESOLVE)
pubmed.ncbi.nlm.nih.gov
- 6OpenAlex record for the RESOLVE report
openalex.org
- 7Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening
pubmed.ncbi.nlm.nih.gov
- 8OpenAlex record for the cessation trial
openalex.org
- 9Early national comparison of robotic versus conventional hip replacements
pubmed.ncbi.nlm.nih.gov
- 10Early national comparison of robotic versus conventional knee replacements
pubmed.ncbi.nlm.nih.gov
- 11OpenAlex record for the hip-replacement study
openalex.org
- 12OpenAlex record for the knee-replacement study
openalex.org
- 13
- 14
- 15
- 16Opportunities and Challenges in Tobacco Treatment
pubmed.ncbi.nlm.nih.gov
- 17Robot assisted hip and knee arthroplasty: It is high tech, but is it better?
pubmed.ncbi.nlm.nih.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.